berkeley pharma ltd Company Information
Company Number
08537849
Website
chemistextra.co.ukRegistered Address
2nd floor grove house, 55 lowlands road, harrow, HA1 3AW
Industry
Other human health activities
Telephone
-
Next Accounts Due
June 2024
Group Structure
View All
Shareholders
prashant ashwin kumar patel 50%
milan ashwin kumar patel 50%
berkeley pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of BERKELEY PHARMA LTD at £1.7m based on a Turnover of £4m and 0.42x industry multiple (adjusted for size and gross margin).
berkeley pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of BERKELEY PHARMA LTD at £0 based on an EBITDA of £-344.7k and a 3.88x industry multiple (adjusted for size and gross margin).
berkeley pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of BERKELEY PHARMA LTD at £0 based on Net Assets of £-245.7k and 2.32x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Berkeley Pharma Ltd Overview
Berkeley Pharma Ltd is a dissolved company that was located in harrow, HA1 3AW with a Companies House number of 08537849. It operated in the other human health activities sector, SIC Code 86900. Founded in May 2013, it's largest shareholder was prashant ashwin kumar patel with a 50% stake. The last turnover for Berkeley Pharma Ltd was estimated at £4m.
Upgrade for unlimited company reports & a free credit check
Berkeley Pharma Ltd Health Check
Pomanda's financial health check has awarded Berkeley Pharma Ltd a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
2 Regular
5 Weak
Size
annual sales of £4m, make it larger than the average company (£678.4k)
- Berkeley Pharma Ltd
£678.4k - Industry AVG
Growth
3 year (CAGR) sales growth of 82%, show it is growing at a faster rate (4.4%)
- Berkeley Pharma Ltd
4.4% - Industry AVG
Production
with a gross margin of 35.1%, this company has a comparable cost of product (35.1%)
- Berkeley Pharma Ltd
35.1% - Industry AVG
Profitability
an operating margin of -8.7% make it less profitable than the average company (6.6%)
- Berkeley Pharma Ltd
6.6% - Industry AVG
Employees
with 12 employees, this is below the industry average (19)
12 - Berkeley Pharma Ltd
19 - Industry AVG
Pay Structure
on an average salary of £22.3k, the company has an equivalent pay structure (£22.3k)
- Berkeley Pharma Ltd
£22.3k - Industry AVG
Efficiency
resulting in sales per employee of £330.9k, this is more efficient (£39.8k)
- Berkeley Pharma Ltd
£39.8k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Berkeley Pharma Ltd
- - Industry AVG
Creditor Days
its suppliers are paid after 120 days, this is slower than average (17 days)
- Berkeley Pharma Ltd
17 days - Industry AVG
Stock Days
it holds stock equivalent to 61 days, this is more than average (14 days)
- Berkeley Pharma Ltd
14 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 8 weeks, this is less cash available to meet short term requirements (128 weeks)
8 weeks - Berkeley Pharma Ltd
128 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 127.2%, this is a higher level of debt than the average (21.3%)
127.2% - Berkeley Pharma Ltd
21.3% - Industry AVG
BERKELEY PHARMA LTD financials
Berkeley Pharma Ltd's latest turnover from March 2020 is estimated at £4 million and the company has net assets of -£245.7 thousand. According to their latest financial statements, Berkeley Pharma Ltd has 12 employees and maintains cash reserves of £182.3 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | May 2014 | |
---|---|---|---|---|---|---|---|
Turnover | |||||||
Other Income Or Grants | |||||||
Cost Of Sales | |||||||
Gross Profit | |||||||
Admin Expenses | |||||||
Operating Profit | |||||||
Interest Payable | |||||||
Interest Receivable | |||||||
Pre-Tax Profit | |||||||
Tax | |||||||
Profit After Tax | |||||||
Dividends Paid | |||||||
Retained Profit | |||||||
Employee Costs | |||||||
Number Of Employees | 12 | 8 | 4 | 4 | |||
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | May 2014 | |
---|---|---|---|---|---|---|---|
Tangible Assets | 8,218 | 2,413 | 2,839 | 3,785 | 4,440 | 5,494 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 8,218 | 2,413 | 2,839 | 3,785 | 4,440 | 5,494 | 0 |
Stock & work in progress | 435,150 | 220,001 | 162,661 | 20,500 | 23,358 | 13,915 | 10,227 |
Trade Debtors | 0 | 191,595 | 149,054 | 55,257 | 5,956 | 371,282 | 306,408 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 275,860 | 35,227 | 34,516 | 146,684 | 276,539 | 0 | 0 |
Cash | 182,270 | 170,780 | 177,170 | 44,845 | 34,433 | 74,225 | 109,792 |
misc current assets | 1,415 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 894,695 | 617,603 | 523,401 | 267,286 | 340,286 | 459,422 | 426,427 |
total assets | 902,913 | 620,016 | 526,240 | 271,071 | 344,726 | 464,916 | 426,427 |
Bank overdraft | 59 | 0 | 36 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 852,356 | 346,741 | 301,608 | 141,055 | 266,030 | 427,275 | 406,139 |
Group/Directors Accounts | 0 | 161,365 | 127,365 | 68,374 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 296,239 | 12,225 | 14,357 | 5,834 | 26,589 | 0 | 0 |
total current liabilities | 1,148,654 | 520,331 | 443,366 | 215,263 | 292,619 | 427,275 | 406,139 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total liabilities | 1,148,654 | 520,331 | 443,366 | 215,263 | 292,619 | 427,275 | 406,139 |
net assets | -245,741 | 99,685 | 82,874 | 55,808 | 52,107 | 37,641 | 20,288 |
total shareholders funds | -245,741 | 99,685 | 82,874 | 55,808 | 52,107 | 37,641 | 20,288 |
Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | May 2014 | |
---|---|---|---|---|---|---|---|
Operating Activities | |||||||
Operating Profit | |||||||
Depreciation | 885 | 426 | 946 | 1,173 | 1,462 | 1,832 | 0 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | |||||||
Stock | 215,149 | 57,340 | 142,161 | -2,858 | 9,443 | 3,688 | 10,227 |
Debtors | 49,038 | 43,252 | -18,371 | -80,554 | -88,787 | 64,874 | 306,408 |
Creditors | 505,615 | 45,133 | 160,553 | -124,975 | -161,245 | 21,136 | 406,139 |
Accruals and Deferred Income | 284,014 | -2,132 | 8,523 | -20,755 | 26,589 | 0 | 0 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | |||||||
Investing Activities | |||||||
capital expenditure | |||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | |||||||
Financing Activities | |||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | -161,365 | 34,000 | 58,991 | 68,374 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | |||||||
interest | |||||||
cash flow from financing | |||||||
cash and cash equivalents | |||||||
cash | 11,490 | -6,390 | 132,325 | 10,412 | -39,792 | -35,567 | 109,792 |
overdraft | 59 | -36 | 36 | 0 | 0 | 0 | 0 |
change in cash | 11,431 | -6,354 | 132,289 | 10,412 | -39,792 | -35,567 | 109,792 |
berkeley pharma ltd Credit Report and Business Information
Berkeley Pharma Ltd Competitor Analysis
Perform a competitor analysis for berkeley pharma ltd by selecting its closest rivals and benchmarking them against 12 key performance metrics.
berkeley pharma ltd Ownership
BERKELEY PHARMA LTD group structure
Berkeley Pharma Ltd has no subsidiary companies.
Ultimate parent company
BERKELEY PHARMA LTD
08537849
berkeley pharma ltd directors
Berkeley Pharma Ltd currently has 2 directors. The longest serving directors include Mr Milan Patel (May 2013) and Mr Prashant Patel (May 2013).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Milan Patel | England | 49 years | May 2013 | - | Director |
Mr Prashant Patel | United Kingdom | 47 years | May 2013 | - | Director |
P&L
March 2020turnover
4m
+80%
operating profit
-345.6k
0%
gross margin
35.2%
+2.82%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2020net assets
-245.7k
-3.47%
total assets
902.9k
+0.46%
cash
182.3k
+0.07%
net assets
Total assets minus all liabilities
berkeley pharma ltd company details
company number
08537849
Type
Private limited with Share Capital
industry
86900 - Other human health activities
incorporation date
May 2013
age
11
accounts
Total Exemption Full
ultimate parent company
previous names
N/A
incorporated
UK
address
2nd floor grove house, 55 lowlands road, harrow, HA1 3AW
last accounts submitted
March 2020
berkeley pharma ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to berkeley pharma ltd.
berkeley pharma ltd Companies House Filings - See Documents
date | description | view/download |
---|